Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Telix-Pharma-Growth

More Like This

PR Newswire associated0

Telix Announces Reorganisation to Deliver on Strategic Priorities

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

PR Newswire associated0

Telix to Present at Jefferies London Healthcare Conference 2023

PR Newswire associated0

Telix Successfully Prices A$650 Million Convertible Bonds

PR Newswire associated0

Telix Announces A$600 Million Convertible Bonds Offering

PR Newswire associated0

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

PR Newswire associated0

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

PR Newswire associated0

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging